Leo Pharma has placed a $70 million bet on the biopharma companies of the future providing more than just pharmacological interventions. The bet takes the form of the Leo Innovation Lab, a site at which the drugmaker will research how apps, web platforms, wearables, virtual reality, artificial intelligence and telemedicine can improve the lives of people with psoriasis.
The antibody experts at arGEN-X have teamed up with dermatology-focused biotech Leo Pharma on a treatment for inflammatory skin diseases, inking a deal worth up to $116 million.
Denmark's LEO Pharma has anted up $1.25 million and some research cash to take an option on an anti-inflammatory program from Germany's 4SC. And if LEO decides to snare the potential treatment for skin diseases like psoriasis, the biotech will pay an additional $4 million followed by milestones that reach up to $120 million.
The sales-rep overtime fight is spreading. Four LEO Pharma salespeople have filed a putative class action, alleging they're owed overtime under U.S. wage-and-hour laws. The reps accuse LEO of...
Novo Nordisk (NYSE: NVO) doesn't like the Greek price cuts. So, instead of discounting its medicines by 25 percent as ordered, it's keeping prices the same on its newest insulin products, forcing
Leo Pharma will reacquire the licensing rights to its topical psoriasis treatments from Warner Chilcott for about $1 billion, the two drugmakers announced today. The deal, which is expected to be
Looking to boost its pipeline for dermatology products, Denmark's LEO Pharma has agreed to buy out Peplin for $287.5 million. The acquisition values Peplin at $16.99 a share and LEO will also extend